DOI QR코드

DOI QR Code

Lack of Association of the MDR1 C3435T Polymorphism with Susceptibility to Gastric Cancer and Peptic Ulcer: a Systemic Review and Meta-analysis

  • Wu, Dan-Dan (Department of Gastroenterology, Renmin Hospital of Wuhan University) ;
  • Zhang, Ji-Xiang (Department of Gastroenterology, Renmin Hospital of Wuhan University) ;
  • Li, Jiao (Department of Gastroenterology, Renmin Hospital of Wuhan University) ;
  • Dong, Wei-Guo (Department of Gastroenterology, Renmin Hospital of Wuhan University)
  • Published : 2014.04.01

Abstract

Background: The multidrug resistance 1 gene (MDR1) C3435T polymorphism has been demonstrated to influence the P-glycoprotein (P-gp) activity level which is related to inflammation and carcinogenesis. This meta-analysis was performed to estimate the association between the MDR1 C3435T polymorphism and the risk of gastric cancer (GC) and peptic ulcer (PU). Materials and Methods: A literature search was conducted with PubMed, Embase and the Cochrane library up to November 2013. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of association. Data were analyzed using Review Manager (Version 5.2), and Stata package (version 12.0) for estimation of publication bias. Results: Six case-control studies were included, of which five were for GC and two for PU. Overall, no evidence was found for any association between the MDR1 C3435T polymorphism and the susceptibility to GC and PU. In the stratified analysis by H. pylori infection status, stage and histology classification of GC, and PU type, there was still no significant association between them. Conclusions: This meta-analysis suggested that the MDR1 C3435T polymorphism is not associated with susceptibility to GC and PU. Large and well-designed studies are warranted to validate our findings.

Keywords

Gastric cancer;peptic ulcer;gastric ulcer;duodenal ulcer;MDR1;polymorphism;meta-analysis

References

  1. Yuan H, Li X, Wu J, et al (2008). Strategies to overcome or circumvent P-glycoprotein mediated multidrug resistance. Curr Med Chem, 15, 470-6. https://doi.org/10.2174/092986708783503258
  2. Tahara T, Arisawa T, Shibata T, et al (2007). Multi-drug resistance 1 polymorphism is associated with reduced risk of gastric cancer in the Japanese population. J Gastroenterol Hepatol, 22, 1678-82. https://doi.org/10.1111/j.1440-1746.2007.04848.x
  3. Wang ZM, Wang T, Bian JN (2013). Association between MDR1 C3435T polymorphism and risk of breast cancer. Gene, 532, 94-9. https://doi.org/10.1016/j.gene.2013.09.050
  4. Wu H, Xu C, Chen G, et al (2013). XRCC1 polymorphism and prognosis of platinum-based chemotherapy in gastric and colorectal cancer: a meta-analysis. J Gastroenterol Hepatol. [Epub ahead of print]
  5. Zhang D, Wang C, Zhou Z (2013). Meta-Analysis of ABCB1 3435C>T Polymorphism and Colorectal Cancer. Pak J Med Sci, 29, 1269-74.
  6. Zintzaras E, Ioannidis JP (2005). Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol, 28, 123-37. https://doi.org/10.1002/gepi.20048
  7. Zou TH, Wang ZH, Fang JY (2013). Positive association between Toll-like receptor 4 gene +896A/G polymorphism and susceptibility to gastric carcinogenesis: a meta-analysis. Tumour Biol, 34, 2441-50. https://doi.org/10.1007/s13277-013-0795-y
  8. Oliveira J, Felipe AV, Chang PY, et al (2012). Association between the C3435T single-nucleotide polymorphism of multidrug resistance 1 gene and risk of gastric cancer. Mol Med Rep, 6, 395-8. https://doi.org/10.3892/mmr.2012.926
  9. Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
  10. Markova S, Nakamura T, Sakaeda T, et al (2006). Genotype-dependent down-regulation of gene expression and function of MDR1 in human peripheral blood mononuclear cells under acute inflammation. Drug Metab Pharmacokinet, 21, 194-200. https://doi.org/10.2133/dmpk.21.194
  11. Mizutani T, Masuda M, Nakai E, et al (2008). Genuine functions of P-glycoprotein (ABCB1). Curr Drug Metab, 9, 167-74. https://doi.org/10.2174/138920008783571756
  12. Piao Y, Liu Z, Ding Z, et al (2013). EGF +61A>G polymorphism and gastrointestinal cancer risk: A HuGE review and meta-analysis. Gene, 519, 26-33. https://doi.org/10.1016/j.gene.2013.01.057
  13. Sabahi Z, Salek R, Heravi RE, et al (2010). Association of gastric cancer incidence with MDR1 gene polymorphism in an ethnic Iranian population. Indian J Cancer, 47, 317-21. https://doi.org/10.4103/0019-509X.64723
  14. Song B, Duan ZY, Zhong YH, et al (2013). Meta-analysis of the MDM2 T309G polymorphism and gastric cancer risk. Asian Pac J Cancer Prev, 14, 6649-51. https://doi.org/10.7314/APJCP.2013.14.11.6649
  15. Sugimoto M, Furuta T, Shirai N, et al (2008). MDR1 C3435T polymorphism has no influence on developing Helicobacter pylori infection-related gastric cancer and peptic ulcer in Japanese. Life Sci, 83, 301-4. https://doi.org/10.1016/j.lfs.2008.06.022
  16. Sung JJ, Kuipers EJ, El-Serag HB (2009). Systematic review: the global incidence and prevalence of peptic ulcer disease. Aliment Pharmacol Ther, 29, 938-46. https://doi.org/10.1111/j.1365-2036.2009.03960.x
  17. Tahara T, Shibata T, Yamashita H, et al (2011). Influence of MDR1 polymorphism on H. pylori-related chronic gastritis. Dig Dis Sci, 56, 103-8. https://doi.org/10.1007/s10620-010-1251-0
  18. Jemal A, Bray F, Center MM, et al (2011). Global Cancer Statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
  19. Higgins JP, Thompson SG (2002). Quantifying heterogeneity in a meta-analysis. Stat Med, 21, 1539-58. https://doi.org/10.1002/sim.1186
  20. Ho GT, Moodie FM, Satsangi J (2003). Multidrug resistance 1 gene (p-glycoprotein 170): an important determinant in gastrointestinal disease? Gut, 52, 759-66. https://doi.org/10.1136/gut.52.5.759
  21. Hoffmeyer S, Burk O, von Richter O, et al (2000). Functional polymorphisms of the human multidrug resistance gene multiple sequence variations and correlation of one allele with p-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA, 97, 3473-8. https://doi.org/10.1073/pnas.97.7.3473
  22. Johnstone RW, Ruefli AA, Smyth MJ (2000). Multiple physiological functions for multidrug transporter P-glycoprotein? Trends Biochem Sci, 25, 1-6. https://doi.org/10.1016/S0968-0004(99)01493-0
  23. Larsen UL, Hyldahl OL, Olesen L, et al (2007). Human intestinal P-glycoprotein activity estimated by the model substrate digoxin. Scand J Clin Lab Invest, 67, 123-34. https://doi.org/10.1080/00365510600986084
  24. Lauren P (1965). The two histological main types of gastric carcinoma: diffuse and so-called intestinal type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand, 64, 31-49. https://doi.org/10.1111/apm.1965.64.1.31
  25. Li X, Qu L, Zhong Y, et al (2013). Association between promoters polymorphisms of matrix metalloproteinases and risk of digestive cancers: a meta-analysis. J Cancer Res Clin Oncol, 139, 1433-47. https://doi.org/10.1007/s00432-013-1446-9
  26. Liu Y, Li L, Qi H, et al (2013). Survivin 231G.C polymorphism and gastrointestinal tract cancer risk: a meta-analysis. PLoS One, 8, 54081. https://doi.org/10.1371/journal.pone.0054081
  27. Lozano R, Naghavi M, Foreman K, et al (2012). Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, 380, 2095-128. https://doi.org/10.1016/S0140-6736(12)61728-0
  28. Breier A, Barancik M, Sulova Z, et al (2005). P-glycoprotein-implications of metabolism of neoplastic cells and cancer therapy. Curr Cancer Drug Targets, 5, 457-68. https://doi.org/10.2174/1568009054863636
  29. Annese V, Valvano MR, Palmieri O, et al (2006). Multidrug resistance 1 gene in inflammatory bowel disease: a meta-analysis. World J Gastroenterol, 12, 3636-44. https://doi.org/10.3748/wjg.v12.i23.3636
  30. Basiri Z, Safaralizadeh R, Bonyadi MJ, et al (2014). Helicobacter pylori vacA d1 genotype predicts risk of gastric adenocarcinoma and peptic ulcers in Northwestern Iran. Asian Pac J Cancer Prev, 15, 1575-9. https://doi.org/10.7314/APJCP.2014.15.4.1575
  31. Begg CB, Mazumdar M (1994). Operating characteristics of a rank correlation test for publication bias. Biometrics, 50, 1088-101. https://doi.org/10.2307/2533446
  32. Chang H, Rha SY, Jeung HC, et al (2010). Association of the ABCB1 3435C>T polymorphism and treatment outcomes in advanced gastric cancer patients treated with paclitaxel-based chemotherapy. Oncol Rep, 23, 271-8.
  33. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88. https://doi.org/10.1016/0197-2456(86)90046-2
  34. Egger M, Davey Smith G, Schneider M, et al (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34. https://doi.org/10.1136/bmj.315.7109.629

Cited by

  1. Association between ABCB1 Immunohistochemical Expression and Overall Survival in Gastric Cancer Patients vol.15, pp.16, 2014, https://doi.org/10.7314/APJCP.2014.15.16.6935
  2. MDR1 C3435T and C1236T Polymorphisms: Association with High-risk Childhood Acute Lymphoblastic Leukemia vol.16, pp.7, 2015, https://doi.org/10.7314/APJCP.2015.16.7.2839
  3. Genetic Variation in the ABCB1 Gene May Lead to mRNA Level Chabge: Application to Gastric Cancer Cases vol.16, pp.18, 2016, https://doi.org/10.7314/APJCP.2015.16.18.8467
  4. Advances and challenges in hereditary cancer pharmacogenetics vol.13, pp.1, 2017, https://doi.org/10.1080/17425255.2017.1233965